Combining PD-L1 expression with tumor-infiltrating immune cells can improve patient selection for immunotherapy, and adopting a dual-target strategy (i.e., the combination of anti-PD-1/PD-L1 and anti-CD31 antibodies) can activate effector T cells while inhibiting tumor angiogenesis, potentially enhancing the effectiveness of immunotherapy for GAC. This evidence concerns the gene PECAM1 and neoplasm.